Clinical Trial: Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06915753) titled 'Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations' on March 31.

Brief Summary: A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Hepatocellular Carcinoma Solid Tumors Solid Tumor, Adult FGFR Gene Amplification...